WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies ...
"Building on the encouraging results from our Phase 2a clinical trial of DA-1241 in patients with presumed MASH, which demonstrated hepatoprotective and glucose-regulating effects, these new ...
DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)--Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, continues to expand ...
BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...
The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 ...
「LINE広告」のコンバージョン計測や最適化の精度向上を実現 LINE株式会社（本社：東京都新宿区、代表取締役社長：出澤 剛）は、広告主が自社サーバーに保有しているデータを、直接LINEに送信可能にする機能「LINE Conversion API」の提供を開始いたしましたの ...
SAN JOSE, Calif.--(BUSINESS WIRE)--Omni Design Technologies, a leader in Wideband Signal Processing™ solutions for the AI data revolution, today announced that it has successfully raised over $35 ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する
フィードバック